SCHEMBL16612467

SCHEMBL16612467

CC1(C)[C@@H]2C[C@H]1C(C=Cc1ccc(O)c(Br)c1)=CC2=O

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CISD1 Q9NZ45 2/20 0.40
PRMT1 Q99873 1/20 0.39
EP300 Q09472 1/20 0.39
MKNK2 Q9HBH9 1/20 0.37
APP P05067 4/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HSP90AA1 P07900 1/20 0.35
LY96 Q9Y6Y9 2/20 0.35
SIRT1 Q96EB6 1/20 0.34
HSD17B3 P37058 1/20 0.34
CARM1 Q86X55 2/20 0.34
F2R P25116 1/20 0.33
LRRK2 Q5S007 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16612466 1.00 CISD1 (0.40) CISD1PRMT1EP300MKNK2APP
SCHEMBL30284593 1.00 CISD1 (0.40) CISD1PRMT1EP300MKNK2APP
SCHEMBL23931239 1.00 CISD1 (0.40) CISD1PRMT1EP300MKNK2APP
SCHEMBL16612465 1.00 CISD1 (0.40) CISD1PRMT1EP300MKNK2APP
SCHEMBL23931236 1.00 CISD1 (0.40) CISD1PRMT1EP300MKNK2APP
SCHEMBL23931238 1.00 CISD1 (0.40) CISD1PRMT1EP300MKNK2APP
SCHEMBL30875107 0.89 LCK (0.45) APPMEN1KMT2ALRRK2
SCHEMBL16612391 0.89 LCK (0.45) APPMEN1KMT2ALRRK2
SCHEMBL30284419 0.89 LCK (0.45) APPMEN1KMT2ALRRK2
SCHEMBL16612660 0.89 LCK (0.45) APPMEN1KMT2ALRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240415787-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2024-12-19 US claimed
EP-4397304-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES Shin Poong Pharmaceutical Co., Ltd. (KR) 2024-07-10 EP claimed
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-07-14 US claimed
EP-2857007-B1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE UNIV KOREA RES & BUS FOUND (KR) 2018-03-28 EP claimed
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-15 US claimed
US-9603842-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2017-03-28 US claimed
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2015-05-28 US claimed
EP-2857007-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE Korea University Research and Business Foundation (KR) 2015-04-08 EP claimed
US-20240415787-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2024-12-19 US disclosed
EP-4397304-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES Shin Poong Pharmaceutical Co., Ltd. (KR) 2024-07-10 EP disclosed
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-07-14 US disclosed
EP-2857007-B1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE UNIV KOREA RES & BUS FOUND (KR) 2018-03-28 EP disclosed
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-15 US disclosed
US-9603842-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2017-03-28 US disclosed
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2015-05-28 US disclosed
EP-2857007-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE Korea University Research and Business Foundation (KR) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE CASP3, DCX, BAX CISD1 1534/4885PRMT1 4295/4885EP300 3118/4885
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease CASP3, DCX, BAX CISD1 1534/4885PRMT1 4295/4885EP300 3118/4885
US-20240415787-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES SMAD3, TGFB1, TGFB2 CISD1 1855/4885PRMT1 2547/4885EP300 233/4885
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE CASP3, DCX, BAX CISD1 1534/4885PRMT1 4295/4885EP300 3118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.